{"disease":{"id":"recurrent-cervical-cancer","name":"recurrent cervical cancer"},"drugs":{"marketed":[{"drug_id":"tisotumab-vedotin","indication_name":"Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"tisotumab-vedotin","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"147","mechanism":"Tisotumab vedotin is a tissue factor (TF)-directed antibody drug conjugate that targets and disrupts microtubule networks in cancer cells."},{"drug_id":"tisotumab","indication_name":"recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"TISOTUMAB","company_name":"Seagen","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"147","mechanism":"Tivdak works by binding to a specific target on cancer cells, triggering an immune response to destroy the cancer."},{"drug_id":"tivdak","indication_name":"Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tisotumab Vedotin","generic_name":"tivdak","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-Drug Conjugate (ADC)","quality_score":10,"revenue":"147","mechanism":""},{"drug_id":"bevacizumab-maly","indication_name":"Persistent, Recurrent, or Metastatic Cervical Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"pembrolizuma","indication_name":"Advanced or recurrent cervical cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06155422","title":"A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":670,"lead_sponsor_name":"Gang Chen (101199)","has_results":false},{"nct_id":"NCT03257267","title":"Study of Cemiplimab in Adults With Cervical Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05798819","title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":424,"lead_sponsor_name":"Guangzhou Gloria Biosciences Co., Ltd.","has_results":false},{"nct_id":"NCT05715840","title":"Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":368,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04191226","title":"Genetic Mutation in Recurrent Cervical Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT06781151","title":"A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04680988","title":"A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04266886","title":"Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07472153","title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"N.N. Alexandrov National Cancer Centre","has_results":false},{"nct_id":"NCT04623333","title":"A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05722288","title":"Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04868708","title":"A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT07141186","title":"QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT06157151","title":"PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Precigen, Inc","has_results":false},{"nct_id":"NCT03816553","title":"SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01693783","title":"Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03439085","title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT01281852","title":"Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07172217","title":"The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT01676818","title":"Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT04380805","title":"A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT02849340","title":"Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false},{"nct_id":"NCT04341883","title":"Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03508570","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02257528","title":"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":26,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07186868","title":"QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03968406","title":"Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03452332","title":"Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04574635","title":"Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03277482","title":"Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04674488","title":"TILs for Treatment of Metastatic or Recurrent Cervical Cancer","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Shanghai OriginCell Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT07081984","title":"Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Therorna","has_results":false},{"nct_id":"NCT02164461","title":"Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Advaxis, Inc.","has_results":true},{"nct_id":"NCT02921269","title":"Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03345784","title":"Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04230954","title":"Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of South Alabama","has_results":false}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}